Previous Article | Next Article 
Journal of Clinical Microbiology, August 2000, p. 2893-2896, Vol. 38, No. 8
0095-1137/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Estimation of Minimum Sterol 14
-Demethylation-Inhibitory
Concentration of Azoles in Candida Yeasts Using
Acetate-Mediated Growth Inhibition: Potential Utility in
Susceptibility Testing
Osamu
Shimokawa* and
Hiroaki
Nakayama
Department of Microbiology, Faculty of
Dentistry, Kyushu University Higashi-ku, Fukuoka 812-8582, Japan
Received 23 December 1999/Returned for modification 1 May
2000/Accepted 29 May 2000
 |
ABSTRACT |
We have recently shown that 14
-demethylation-deficient cells of
Candida albicans are subject to growth arrest by 0.24 M
acetate in a yeast extract-peptone-glucose medium and that the minimum concentration of an azole antifungal agent required for total inhibition of sterol 14
-demethylation (MDIC for minimum
demethylation-inhibitory concentration) is practically identical to
its MIC determined in the acetate-supplemented medium (O. Shimokawa and
H. Nakayama, Antimicrob. Agents Chemother. 43:100-105, 1999). In the
present study we estimated the MDICs of three different azoles
(fluconazole, ketoconazole, and itraconazole) for strains of various
Candida species using this method and compared them with
the MICs determined in the corresponding acetate-free medium. The
results demonstrated that the test strains were divided into two
classes. One class of strains was characterized by tolerance to
14
-demethylation deficiency (MIC > MDIC) and consisted of
strains of C. albicans, C. guilliermondii,
C. kefyr, and C. tropicalis. The other class was intolerant to 14
-demethylation deficiency (MIC
MDIC) and comprised strains of C. glabrata, C. krusei, and C. parapsilosis. We also showed that
replacement of the yeast extract-peptone-glucose medium with RPMI 1640 medium did not affect the results substantially. Furthermore, the 80%
inhibitory concentration (IC80) in RPMI 1640 medium,
recommended as a substitute for the conventional MIC in susceptibility testing, was found to be close to the MDIC.
 |
INTRODUCTION |
Azole antifungal agents inhibit
sterol 14
-demethylation (referred to as 14-dMe) in ergosterol
biosynthesis, thus causing the accumulation of 14
-methylated sterols
in the fungal membranes. Notably, however, the effect of 14-dMe
inhibition on cell growth is not simple. While cells of some fungi
cannot grow in the presence of 14-dMe deficiency (i.e., they are
intolerant to 14-dMe deficiency), those of other fungi can (i.e., they
are tolerant to 14-dMe deficiency). Thus far, Saccharomyces
cerevisiae has been thought to belong to the former class
(3), whereas Candida albicans has been thought to
belong to the latter class (2, 3, 7, 9, 10). On the other
hand, it is generally assumed that 14-dMe inhibition constitutes the
basis of the therapeutic efficacies of azole antifungal agents. In
effect, there is evidence that C. albicans cells grown under
conditions of 14-dMe deficiency show increased susceptibility to the
fungicidal mechanisms of phagocytes (8, 11), suggesting that
the clinical efficacies of this class of drugs are brought about by
cooperation of 14-dMe inhibition and host defense mechanisms.
In fungi intolerant to 14-dMe deficiency, the minimum concentration of
an azole drug required for a complete inhibition of 14-dMe (MDIC
[12] for minimum demethylation-inhibitory
concentration) is expected to be equal or at least close to its MIC.
However, for fungi tolerant to 14-dMe deficiency, for which the MDIC is lower than the MIC by definition, the MIC gives no information about
the MDIC, which should be important in clinical settings. Previously,
we have described a simple method for estimation of the MDIC of an
azole for C. albicans (12). That method uses growth inhibition by acetate in 14-dMe-deficient cells and determines the MIC in an acetate-containing yeast extract-peptone-glucose (YEPG)
medium. In the present study, we found, by using this method, that some
species of the genus Candida were tolerant to 14-dMe deficiency, like C. albicans, while others were not.
Furthermore, we also showed that measurement of the 80% inhibitory
concentration (IC80) in a special medium, now widely used
as a routine medium for azole susceptibility testing, gave results
fairly close to the MDIC estimate.
 |
MATERIALS AND METHODS |
Fungal strains.
The fungal strains used in this study are
listed in Table 1.
Culture media.
YEPG medium and acetate (0.24 M)-supplemented
YEPG (YEPG-Ac) medium were described previously (12). YEPG
and YEPG-Ac were solidified with 2% (wt/vol) agar to give YEPG agar
and YEPG-Ac agar, respectively. The RPMI 1640 medium (RPMI) was as
described previously (5), and it was supplemented with 0.24 M sodium acetate to give RPMI-Ac. Azole drugs were dissolved in
dimethyl sulfoxide and were added to sterile media, with the final
concentration of the solvent being adjusted to 1% (vol/vol).
Agar plate assays of azole susceptibility.
Assays with YEPG
or YEPG-Ac agar plates containing a concentration gradient of an azole
were done as described previously (12).
MIC measurement and estimation of MDIC by dilution assay.
A
test cell suspension (107 CFU/ml) was prepared by washing
and suspending in distilled water cells grown in YEPG at 35°C
overnight with shaking. The conventional MIC of an azole was measured
as follows. Twofold dilutions (0.1 ml each) of the test drug made in
YEPG or RPMI were mixed in plastic microplate wells with 0.1-ml aliquots of a 100-fold dilution of the cell suspension made in the same
medium (containing 104 CFU), and the plates were incubated
at 35°C for 2 days without agitation. The lowest drug concentration
that gave a visibly clear culture was taken to represent the MIC. It
should be noted that the MIC thus obtained is not equivalent to the
IC80 (see below) determined by the routine standardized by
the National Committee for Clinical Laboratory Standards (5)
even when RPMI is used. The MDIC of an azole was estimated by measuring
the MIC in YEPG-Ac or RPMI-Ac (signified by MICAc) in a way
similar to that described above.
Determination of IC80 of the azole.
Determination of the IC80 of the azole was carried out in
RPMI by the method standardized by the National Committee for Clinical Laboratory Standards (5). Thus, dilution assays were done
with RPMI as described above, and the drug concentration that caused 80% growth inhibition was determined by turbidimetry, followed by
interpolation when appropriate.
Sterol analysis.
Extraction of cellular lipids and
thin-layer chromatography on silica gel plates (Merck) were carried out
as described previously (9). Identification of sterols was
achieved by comparing the Rfs with the reference
values obtained in our previous work (9).
Chemicals.
Fluconazole (FLCZ) was donated by Pfizer
Pharmaceuticals (Tokyo, Japan); ketoconazole (KCZ) and itraconazole
(ITZ) were gifts from the Janssen Research Foundation (Beerse, Belgium).
 |
RESULTS |
Relationship between 14-dMe deficiency and acetate-mediated growth
inhibition in Candida species.
We have previously
shown that azole-treated C. albicans cells are subject to
growth inhibition in YEPG-Ac and that the extent of this inhibition
increases as the degree of 14-dMe (the level of cellular ergosterol)
diminishes, finally becoming complete when the azole concentration is
high enough to make the ergosterol undetectable (12). (In a
previous study [12], some cell growth can be seen in
YEPG-Ac even in the virtual absence of 14-dMe [Fig. 5A therein],
giving the impression that the MICAc is higher than the
MDIC. However, this is due to the high initial cell density (
5 × 105 CFU/ml; A540
0.04)
needed for sterol analysis, combined with gradual growth cessation
intrinsic to azole-treated cells [see Fig. 4A of reference
12]. In MIC assays, an initial cell density of
5 × 104 CFU/ml is used [see Materials and
Methods], with which the residual growth alone barely yields visible
turbidity. Hence, the MICAc roughly coincides with MDIC.)
On the basis of these observations, we have proposed that the MDICs of
azoles can be estimated by determining the MICAc,
i.e., the MIC measured in YEPG-Ac (12).
To probe the possibility of generalization of this finding, we
subjected strains of different
Candida species other than
C. albicans to the same analysis used in the previous study
(
12).
Briefly, cells were grown on YEPG agar along a
concentration gradient
of FLCZ, and the sterol profiles for cells from
different parts
of the gradient were monitored and were compared with
the growth
pattern on YEPG-Ac agar that contained the same gradient.
The
results obtained were consistent with the above-mentioned
correlation
previously demonstrated for
C. albicans strains (Fig.
1
and
2).
In essence, when growth on
YEPG-Ac agar with an FLCZ gradient
was diminished or
undetectable, the ergosterol content of the
cells from the
corresponding position of YEPG agar with an FLCZ
gradient was likewise
diminished or undetectable. Judging from
these findings, we considered
that YEPG-Ac should be useful for
estimation of the MDIC for
Candida species other than
C. albicans as well.

View larger version (92K):
[in this window]
[in a new window]
|
FIG. 1.
Growth of Candida strains on a concentration
gradient of FLCZ. (A) YEPG agar; (B) YEPG-Ac agar. Top, photographic
images; bottom, schematic representations with gradations depicting
growth. FLCZ concentrations, 0 to 10 µg/ml from left to right (I to
IV). Rows: 1, C. tropicalis 820567; 2, C. kefyr
B2455; 3, C. parapsilosis MCC499; 4, C. guilliermondii IFO0454; 5, C. glabrata CBS138; 6, C. krusei B2399.
|
|

View larger version (46K):
[in this window]
[in a new window]
|
FIG. 2.
Thin-layer chromatography analysis of sterols from cells
grown on a YEPG agar plate containing the FLCZ concentration gradient
(plate A in Fig. 1). Lanes: 1, C. tropicalis 820567; 2, C. kefyr B2455; 3, C. parapsilosis MCC499; 4, C. guilliermondii IFO0454; 5, C. glabrata CBS138;
6, C. krusei B2399; I to IV, sampling zones (see Fig. 1).
Identification of sterols: a, ergosterol; b, 4,14-methylated sterols;
c, 4,4',14-methylated sterols.
|
|
Relationship between MIC and MICAc (MDIC) of the
azole.
On the basis of the results presented above, we went on to
determine the MICAc and MIC using YEPG-Ac and YEPG,
respectively, with three different azoles and a wider array of strains
of the genus Candida (Table
2). A strain of S. cerevisiae
was included as a reference. It has been reported that cells of
S. cerevisiae are incapable of growth in the absence of
14-dMe (3). In accordance with this notion, the
MICAc and MIC of each of the azoles used were shown to be
identical for the test strain of this yeast. On the other hand, for all
C. albicans strains except B59630 the MICAc was
much lower than the MIC. Strain B59630 is an azole-resistant mutant
(6) which overexpresses the drug efflux pump Cdr1
(1). While the MIC did not distinguish B59630 from the other
C. albicans test strains, the MICAc did:
compared with the other strains, the MICs of all three azoles for
strain B59630 were elevated, with the increase being most marked with FLCZ. Notably, however, this strain was found to be similar to the
others in terms of the relationship between the MICAc and the MIC: the MICAc and MIC were sharply different from each
other for KCZ and ITZ, although they were fairly close to each other for FLCZ due to the marked increase in the MICAc. The test
strains of C. glabrata, C. krusei, and
C. parapsilosis were similar to S. cerevisiae in
this respect; differences between the MICAc and the MIC
were absent or only slight, with the factor being not more than 2. The
behaviors of the strains of C. guilliermondii, C. kefyr, and C. tropicalis were similar to those of the
C. albicans strains, with the MICAc being lower
than the MIC at least by an order of magnitude.
Comparison of YEPG and RPMI.
As a routine of the clinical
laboratory, azole susceptibility testing is done by measuring the
IC80 in RPMI by the standard procedure (5). For
this reason, we wanted to see what would happen if YEPG was replaced by
RPMI in our assay. We found that the RPMI-based MICAc and
MIC of FLCZ were similar, if not identical, to the YEPG-based
counterparts (Table 3).
Coincidence between IC80 and MICAc
(MDIC).
We also compared the MICAc and the MIC with
the IC80 and found that the IC80 was close to
the MICAc, the estimated MDIC, for FLCZ (Table 3). It is
this feature of IC80 that probably made possible the
identification of the FLCZ-specific azole resistance in B59630
(6).
 |
DISCUSSION |
The utility of acetate-mediated growth inhibition for estimation
of the MDICs of azoles has previously been demonstrated with strains of
C. albicans (12). In the present study, it was
extended to other Candida species (Fig. 1 and 2), which
justified comparison of the MDIC, as estimated from the
MICAc, and the MIC with a larger set of strains of the
genus Candida (Table 2). We found that the test strains were
clearly divided into two distinct classes irrespective of the azole
used. For one class, the MDICs and MICs were practically identical,
indicating that cells were intolerant to 14-dMe deficiency; for the
other class, the MDICs were much lower than MICs, indicating that the
cells were tolerant to 14-dMe deficiency. It is unclear whether the
tolerance or intolerance to 14-dMe deficiency is a species-dependent
phenotype. While C. albicans may possibly be homogeneous
with respect to this trait, there is no reason to believe that other
species may also be so. More strains must be tested before a conclusion
can be drawn.
The dichotomy between tolerance and intolerance to 14-dMe deficiency
has two practical aspects that are worth mentioning. First, it has
nothing to do with the MICAc-based estimation of the MDIC,
the information that should be needed for clinical purposes (8,
11), and hence will cause no problem in the use of
MICAc as the key parameter in azole susceptibility testing.
Second, the possibility exists that azoles might be clinically more
effective against fungi intolerant to 14-dMe deficiency than those
tolerant to 14-dMe deficiency. This is because fungal cells of the
latter class are still capable of growth under 14-dMe-deficient
conditions and their control within the human body is perhaps more
dependent on the host's defense mechanisms.
The test results with RPMI are also of note. First, the
MICAc (as well as the MIC) measured by use of RPMI and YEPG
were practically equivalent. Since RPMI is nutritionally much poorer
than YEPG for Candida yeasts, this finding seems to suggest
that the choice of the basal medium is not of critical importance in
the determination of the MICAc (and, hence, in the
estimation of the MDIC). Second, the finding that the IC80
(RPMI-based) is in effect close to the MDIC should be significant
because it gives some basis to the totally empirical parameter
IC80. However, as a tool for estimation of the MDIC, the
YEPG-based MICAc has the obvious advantage of being
theoretically well based, simple to measure, accurate, and inexpensive.
The underlying mechanism(s) for the dichotomy with regard to the effect
of 14-dMe deficiency on cell growth is an interesting question that
remains to be answered. We consider the isolation of mutants with
alterations in this trait to be the approach of choice. Studies
along this line are under way in the authors' laboratory. Also worth
study is the applicability of the present method to azole
susceptibility testing of filamentous fungi. This possibility is
intriguing in view of the lack of a convenient procedure suitable
for this purpose.
 |
ACKNOWLEDGMENTS |
We thank F. C. Odds of the Janssen Research Foundation and
R. D. Cannon and M. Niimi, both of the University of Otago, for providing us with fungus strains. The gifts of azole drugs from Pfizer
Pharmaceuticals and Janssen Research Foundation are gratefully acknowledged. Thanks are also due to K. Sakai for general supportive services in the laboratory.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Microbiology, Faculty of Dentistry, Kyushu University, Higashi-ku,
Fukuoka 812-8582, Japan. Phone: 81-92-642-6332. Fax: 81-92-642-6263;
E-mail: simo{at}dent.kyushu-u.ac.jp.
 |
REFERENCES |
| 1.
|
Albertson, G. D.,
M. Niimi,
R. D. Cannon, and H. F. Jenkinson.
1996.
Multiple efflux mechanisms are involved in Candida albicans fluconazole resistance.
Antimicrob. Agents Chemother.
40:2835-2841[Abstract].
|
| 2.
|
Bard, M.,
N. D. Lees,
R. J. Barbuch, and D. Sanglard.
1987.
Characterization of a cytochrome P450 deficient mutant of Candida albicans.
Biochem. Biophys. Res. Commun.
147:794-800[CrossRef][Medline].
|
| 3.
|
Bard, M.,
N. D. Lees,
T. Turi,
D. Craft,
L. Cofrin,
R. Barbuch,
C. Koegel, and J. C. Loper.
1993.
Sterol synthesis and viability of erg11 (cytochrome P450 lanosterol demethylase) mutations in Saccharomyces cerevisiae and Candida albicans.
Lipids
28:963-967[Medline].
|
| 4.
|
Fonzi, W. A., and M. Y. Irwin.
1993.
Isogenic strain construction and gene mapping in Candida albicans.
Genetics
134:717-728[Abstract].
|
| 5.
|
National Committee for Clinical Laboratory Standards.
1992.
Reference method for broth dilution antifungal susceptibility testing of yeast. Proposed standard M27-P.
National Committee for Clinical Laboratory Standards, Wayne, Pa.
|
| 6.
|
Odds, F. C.
1992.
Antifungal susceptibility testing of Candida spp. by relative growth measurement at single concentrations of antifungal agents.
Antimicrob. Agents Chemother.
36:1727-1737[Abstract/Free Full Text].
|
| 7.
|
Pierce, A. M.,
H. D. Pierce,
A. M. Unrau, and A. Oehlschlager.
1978.
Lipid composition and polyene antibiotic resistance of Candida albicans mutants.
Can. J. Biochem.
56:135-142[Medline].
|
| 8.
|
Shigematsu, M. L.,
J. Uno, and T. Arai.
1981.
Correlative studies on in vivo and in vitro effectiveness of ketoconazole against Candida albicans infection.
Jpn. J. Med. Mycol.
22:195-201.
|
| 9.
|
Shimokawa, O.,
Y. Kato, and H. Nakayama.
1986.
Accumulation of 14-methyl sterols and defective hyphal growth in Candida albicans.
J. Med. Vet. Mycol.
24:327-336[Medline].
|
| 10.
|
Shimokawa, O.,
Y. Kato,
K. Kawano, and H. Nakayama.
1989.
Accumulation of 14 -methylergosta-8,24(28)-dien-3 ,6 -diol in 14 -demethylation mutant of Candida albicans: genetic evidence for the involvement of 5-desaturase.
Biochim. Biophys. Acta
1003:15-19[Medline].
|
| 11.
|
Shimokawa, O., and H. Nakayama.
1992.
Increased sensitivity of Candida albicans cells accumulating 14 -methylated sterols to active oxygen: possible relevance to in vivo efficacies of azole antifungal agents.
Antimicrob. Agents Chemother.
36:1626-1629[Abstract/Free Full Text].
|
| 12.
|
Shimokawa, O., and H. Nakayama.
1999.
Acetate-mediated growth inhibition in sterol 14 -demethylation-deficient cells of Candida albicans.
Antimicrob. Agents Chemother.
43:100-105[Abstract/Free Full Text].
|
| 13.
|
Sikorski, R. S., and P. Hieter.
1989.
A system of shuttle vectors and yeast host strains designed for efficient manipulation of DNA in Saccharomyces cerevisiae.
Genetics
122:19-27[Abstract/Free Full Text].
|
| 14.
|
Whelan, W. L., and P. T. Magee.
1981.
Natural heterozygosity in Candida albicans.
J. Bacteriol.
145:896-903[Abstract/Free Full Text].
|
Journal of Clinical Microbiology, August 2000, p. 2893-2896, Vol. 38, No. 8
0095-1137/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Shimokawa, O., Niimi, M., Kikuchi, K., Saito, M., Kajiwara, H., Yoshida, S.-i.
(2005). Relationship between MIC and Minimum Sterol 14{alpha}-Demethylation-Inhibitory Concentration as a Factor in Evaluating Activities of Azoles against Various Fungal Species. J. Clin. Microbiol.
43: 5547-5549
[Abstract]
[Full Text]
-
Moosa, M.-Y. S., Sobel, J. D., Elhalis, H., Du, W., Akins, R. A.
(2004). Fungicidal Activity of Fluconazole against Candida albicans in a Synthetic Vagina-Simulative Medium. Antimicrob. Agents Chemother.
48: 161-167
[Abstract]
[Full Text]
-
Rex, J. H., Pfaller, M. A., Walsh, T. J., Chaturvedi, V., Espinel-Ingroff, A., Ghannoum, M. A., Gosey, L. L., Odds, F. C., Rinaldi, M. G., Sheehan, D. J., Warnock, D. W.
(2001). Antifungal Susceptibility Testing: Practical Aspects and Current Challenges. Clin. Microbiol. Rev.
14: 643-658
[Abstract]
[Full Text]